THT provides gamma-sterilized, human placenta–derived ECM proteins.
The Austrian company is a new supplier for our portfolio of animal-component-free materials and offers human ECMs e.g. laminin-111, collagen type I & IV for 3D cancer culture and more.
THT Biomaterials, a Vienna-based biotech startup and founded in 2020, develops biomimetic materials derived from human placenta. They isolate extracellular matrix (ECM) proteins such as Collagen-I and Laminin-111 to replace animal-derived components in cell culture. This creates a more natural, human-relevant environment for research and medicine. They offer gamma-sterilized human-derived ECM proteins for applications in cell attachment, coating, sprouting, and advanced cancer models.
Native human collagen-I
Gamma-sterilized human atelocollagen type I prepared from human placenta
App.: cell attachment, coating, sprouting experiments
Native human collagen-IV
Gamma-sterilized human collagen type IV prepared from human placenta
App.: cell attachment, coating
Native human laminin-111
Gamma-sterilized human laminin-111 prepared from human placenta
App.: cell attachment, coating, animal-free 2D & 3D cancer cell culture
Human placenta substrate
Gamma-sterilized human extracellular matrix (ECM) proteins from human placenta
App.: cell attachment, coating,
Human placenta ECM, powder
Gamma-sterilized human extracellular matrix (ECM) proteins from human placenta
App.: cell attachment, coating, sprouting experiments
--------------------------------------------------------
Download the overview flyer here.
Have more questions? Contact us here.
References:
Frequently Used Strategies to Isolate Extracellular Matrix Proteins from Human Placenta and Adipose Tissue; Tissue Eng Part C Methods. 2021 Dec; 27(12):649-660. doi: 10.1089/ten.TEC.2021.0150.
More References here.
